Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Who Have Achieved a Complete Hematologic Remission, Complete Cytogenetic Remission, and Major Molecular Remission, But Not a Complete Molecular Remission on a Tyrosine Kinase Inhibitor Alone.
Conditions
Interventions
Nilotinib
Ruxolitinib
Locations
2
United States
The University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Start Date
January 1, 2018
Primary Completion Date
August 1, 2021
Completion Date
August 1, 2021
Last Updated
February 16, 2021
NCT07549516
NCT02852486
NCT02389920
Lead Sponsor
University of Michigan Rogel Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions